newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

  • AEON Biopharma reported positive FDA Type 2a meeting feedback supporting ABP-450's comparative analytical strategy under the 351(k) pathway
  • The company strengthened its balance sheet via a $6 million PIPE financing & Daewoong note exchange, reducing outstanding debt by over 90%
  • John Bencich was appointed as Chief Financial Officer with over 25 years of leadership experience
  • AEON plans to complete the majority of its analytical comparability program in 2026 & request a Type 2b meeting later in the year
  • The company reported $6.2 million in cash & cash equivalents as of March 31, 2026, with operations expected to be funded into the third quarter of 2026
  • Scientific data on primary structure comparability between ABP-450 & BOTOX was presented at the 2026 American Academy of Neurology meeting
  • An abstract on structural & functional comparability will be presented at the American Headache Society Annual Meeting on June 4-7, 2026
  • AEON reported a net loss of $11.793 million for the first quarter of 2026 compared to net income of $9.095 million in the same period last year